# HCC (NCT05134532)

> Regorafenib After Progression on Atezolizumab Plus Bevacizumab in Advanced HCC

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05134532
- Phase: PHASE2
- Status: UNKNOWN
- Sponsor: CHA University
- Conditions: Hepatocellular Carcinoma
- Interventions: regorafenib
- Enrollment: 40
- Primary outcome: Progression-free survival (PFS) by RECIST v 1.1

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- Bluesky threads: 120
- Podcasts: 1
- X threads: 1

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=hcc-nct05134532

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05134532", "email": "<work email>"}; the inbox owner confirms by the emailed link.